Post by digdeeper1976 on Sept 14, 2016 10:48:04 GMT -5
Revised timeline based on the September 7th announcement that they had dosed the first HBV patient with 521.
0.6 mg/kg was dosed around June 16 2016
1 mg/kg was dosed around July 15 2016
2 mg/kg was dosed around August 13 2016
Keeping with the 29 day time line between doses
4 mg/kg will be given around September 10
5 mg/kg will be given around October 9
6 mg/kg will be given around November 7 2016
CHB patients receiving 3 doses of ARC-521 Injection
2 mg/kg first dos Around September 12 2016
2 mg/kg second dose around October 10
2 mg/kg third dose around November 7 2016
4 mg/kg first dose Around October 10
4 mg/kg second dose around November 7
4 mg/kg third dose around December 5
6 mg/kg first dose Around December 6
6 MG/kg second dose around January 3
6 mg/kg third dose around January 31
85 days will put the end of the study around April 26th 2017.
This is dosing all participants at the absolute first available time.
The study Protocol calls for a 60 day screening period prior to enrollment. Based on that they will need to have the cohorts ready to go before they are able to move to the next dose level.
The study has a primary completion date of June 2017. This does not leave much room for delays.
0.6 mg/kg was dosed around June 16 2016
1 mg/kg was dosed around July 15 2016
2 mg/kg was dosed around August 13 2016
Keeping with the 29 day time line between doses
4 mg/kg will be given around September 10
5 mg/kg will be given around October 9
6 mg/kg will be given around November 7 2016
CHB patients receiving 3 doses of ARC-521 Injection
2 mg/kg first dos Around September 12 2016
2 mg/kg second dose around October 10
2 mg/kg third dose around November 7 2016
4 mg/kg first dose Around October 10
4 mg/kg second dose around November 7
4 mg/kg third dose around December 5
6 mg/kg first dose Around December 6
6 MG/kg second dose around January 3
6 mg/kg third dose around January 31
85 days will put the end of the study around April 26th 2017.
This is dosing all participants at the absolute first available time.
The study Protocol calls for a 60 day screening period prior to enrollment. Based on that they will need to have the cohorts ready to go before they are able to move to the next dose level.
The study has a primary completion date of June 2017. This does not leave much room for delays.